OVERSEA CHINESE BANKING Corp Ltd Purchases Shares of 41,673 Abbott Laboratories $ABT

OVERSEA CHINESE BANKING Corp Ltd acquired a new position in shares of Abbott Laboratories (NYSE:ABT) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 41,673 shares of the healthcare product maker’s stock, valued at approximately $3,851,000.

Other institutional investors also recently modified their holdings of the company. Brighton Jones LLC increased its position in Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after buying an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC boosted its holdings in Abbott Laboratories by 3.5% in the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after acquiring an additional 162 shares in the last quarter. United Bank grew its stake in Abbott Laboratories by 7.4% in the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after acquiring an additional 2,001 shares during the period. Main Street Financial Solutions LLC increased its holdings in shares of Abbott Laboratories by 13.6% during the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock valued at $1,618,000 after acquiring an additional 1,428 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its position in shares of Abbott Laboratories by 25.6% during the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock worth $195,267,000 after purchasing an additional 292,547 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott’s First Wearable Device for Dual Ketone and Glucose Tracking
• Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott’s next-generation Amulet 360 device receives CE Mark
• Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise
• Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns.
• Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains

Analysts Set New Price Targets

A number of analysts have commented on ABT shares. TD Cowen boosted their price target on shares of Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, August 25th. Piper Sandler reissued an “overweight” rating and set a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. BTIG Research upped their target price on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a report on Friday, July 17th. UBS Group cut their price target on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Finally, Robert W. Baird began coverage on Abbott Laboratories in a research note on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price objective for the company. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $112.63 on Monday. The stock has a market cap of $194.89 billion, a P/E ratio of 36.45, a P/E/G ratio of 2.18 and a beta of 0.59. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The company’s 50 day moving average price is $102.61 and its two-hundred day moving average price is $100.14. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same period last year, the business posted $1.26 earnings per share. Abbott Laboratories’s revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were given a dividend of $0.63 per share. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.